- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04435717
Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01) (COVITOZ-01)
Unicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19
Aperçu de l'étude
Statut
Les conditions
Description détaillée
National, unicenter, randomized, open-label, controlled phase II clinical trial with a drug marketed and administered under conditions of use other than those approved.
The study is designed to evaluate the effect of adding Tocilizumab to standard or standard of care for patients infected with COVID-19 and diagnosed with mild-moderate pneumonia.
78 patients are expected to be included in the study in a single center in Spain. The study includes a selection and randomization period, and a 28-day follow-up period (or until death, or premature withdrawal, whichever is earlier). Once the patients complete the study, they will continue with their usual follow-up.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Madrid, Espagne, 28034
- Hospital Universitario Ramón y Cajal
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients over 18 years of age who have given their informed consent. This will be collected verbally and will be recorded in the medical record by the investigating doctor.
The patient is diagnosed with mild-moderate SARS-CoV-2 pneumonia confirmed microbiologically ≤7 days before randomization, and presents:
to. Basal oxygen saturation> 90% b. CURB-65 ≤1 c. PaO2 / FiO2≥300 or SatO2 / FiO2≥315
- The patient is hospitalized or meets hospital admission criteria.
- The patient is not expected to enter the ICU or die in the next 24 hours.
Exclusion Criteria:
- Participants in another simultaneous clinical trial.
- Use of other immunomodulators.
- Coinfection with the hepatitis B virus (detectable AgSup-HBV).
- Pregnancy (or planning to become pregnant during the course of the study), or lactation period.
- Presence of laboratory abnormalities of grade ≥ 4.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: TCZ 8 mg / kg one dose
TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment
|
Tocilizumab 20 MG/ML Intravenous (one dose)
|
Expérimental: TCZ 8 mg / kg in two
TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment
|
Tocilizumab 20 MG/ML Intravenous ( two doses)
Autres noms:
|
Aucune intervention: standard care treatment
Usual / standard care treatment
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.
Délai: Day1 and Day3.
|
Average increase in IL-12 values in the 3 study groups from the start of treatment (D0) and on days D + 1 and D + 3.
|
Day1 and Day3.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Progression of pneumonia
Délai: Day3, Day7 and Day28
|
Percentage of patients per group with progression of pneumonia in Day3, Day 7 and Day28
|
Day3, Day7 and Day28
|
PaO2/FiO2
Délai: Day3, Day7 and Day28
|
Proportion of patients with PaO2 / FiO2 <300 (or SatO2 / FiO2 ≤315) at some point in the evolution.
|
Day3, Day7 and Day28
|
cause mortality to 28 days after started treatment
Délai: Day3, Day7 and Day28
|
cause mortality to 28 days after started treatment
|
Day3, Day7 and Day28
|
Length of hospital stay
Délai: Day3, Day7 and Day28
|
Length of hospital stay
|
Day3, Day7 and Day28
|
patients requiring Intensive Care Unit admission
Délai: Day3, Day7 and Day28
|
Percentage of patients requiring Intensive Care Unit admission
|
Day3, Day7 and Day28
|
evolution of inflammatory parameters IL12
Délai: Day0, Day3 and Day7
|
IL-12 levels at Day 7
|
Day0, Day3 and Day7
|
evolution of inflammatory parameters IL-10, IL-1, IL-6, IL-17 and IFN-gamma
Délai: Day0, Day3 and Day7
|
IL-10, IL-1, IL-6, IL-17 and IFN-gamma levels on days Day 0, Day1, Day 3 and Day 7
|
Day0, Day3 and Day7
|
evolution of inflammatory parameters Procalcitonin (PCT),
Délai: Day0, Day3 and Day7
|
Procalcitonin (PCT), levels on days Day0, Day1, Day3 and Day 7
|
Day0, Day3 and Day7
|
evolution of inflammatory parameters C-reactive protein (PCR),
Délai: Day0, Day3 and Day7
|
C-reactive protein (PCR),levels on days Day0, Day1, Day3 and Day 7
|
Day0, Day3 and Day7
|
evolution of inflammatory parameters D-dimer
Délai: Day0, Day3 and Day7
|
D-dimer levels on days Day0, Day1, Day3 and Day 7
|
Day0, Day3 and Day7
|
evolution of inflammatory parameters and ferritin
Délai: Day0, Day3 and Day7
|
ferritin levels on days Day0, Day1, Day3 and Day 7
|
Day0, Day3 and Day7
|
pharmacokinetics of tocilizumab Cmin
Délai: Day0, Day1 Day3 and Day7
|
Cmin,on Day0, Day1, Day3 and Day7.
On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
|
Day0, Day1 Day3 and Day7
|
pharmacokinetics of tocilizumab Cmax
Délai: days Day0, Day1 Day3 and Day7
|
Cmax,on Day0, Day1, Day3 and Day7.
On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
|
days Day0, Day1 Day3 and Day7
|
pharmacokinetics of tocilizumab Cmedia
Délai: days Day0, Day1 Day3 and Day7
|
Cmedia,on Day0, Day1, Day3 and Day7.
On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
|
days Day0, Day1 Day3 and Day7
|
pharmacokinetics of tocilizumab Tmax
Délai: days Day0, Day1 Day3 and Day7
|
Tmax,on Day0, Day1, Day3 and Day7.
On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
|
days Day0, Day1 Day3 and Day7
|
pharmacokinetics of tocilizumab AUC
Délai: days Day0, Day1 Day3 and Day7
|
AUC,on Day0, Day1, Day3 and Day7.
On day 0 (D0), blood samples will be collected 12 hours after the infusion of each dose of tocilizumab in both experimental treatment groups.
|
days Day0, Day1 Day3 and Day7
|
Adverse event
Délai: days Day0, Day3, Day7 and Day28
|
Serious and non-serious adverse events.
|
days Day0, Day3, Day7 and Day28
|
Adverse event to cause the treatment interruption.
Délai: days Day0, Day3, Day7 and Day28
|
Adverse events to cause the treatment interruption.
|
days Day0, Day3, Day7 and Day28
|
Adverse event Abnormalities in laboratory
Délai: days Day0, Day3, Day7 and Day28
|
Abnormalities in laboratory findings unrelated to COVID-19 disease.
|
days Day0, Day3, Day7 and Day28
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- COVITOZ-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Covid19
-
Anavasi DiagnosticsPas encore de recrutement
-
Ain Shams UniversityRecrutement
-
Israel Institute for Biological Research (IIBR)Complété
-
Colgate PalmoliveComplété
-
Christian von BuchwaldComplété
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActif, ne recrute pas
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichInscription sur invitation
-
Alexandria UniversityComplété
Essais cliniques sur Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityComplétéSyndrome de libération de cytokines | Pneumonie Covid-19Pakistan
-
Instituto Nacional de Cancerologia de MexicoRoche Pharma AGActif, ne recrute pas
-
University Hospital for Infectious Diseases, CroatiaInconnueCOVID-19 [feminine] | Pneumonie sévèreCroatie
-
Christian HassagerComplétéSyndrome de réponse inflammatoire systémique | Arrêt cardiaque | Arrêt cardiaque hors hôpitalDanemark
-
AstraZenecaQuotient SciencesComplété
-
Rigshospitalet, DenmarkComplétéComportement appétitif | Stress physique | Inhibition de l'interleukine-6Danemark
-
Centre Hospitalier Universitaire, AmiensComplétéDouleur, Postopératoire | Anesthésie localeFrance
-
Dompé Farmaceutici S.p.AComplétéKératite | Kératite neurotrophique | Ulcère cornéenAllemagne, Italie, France, Pologne, Espagne, Royaume-Uni
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Noordwest ZiekenhuisgroepActif, ne recrute pasAdénocarcinome de l'œsophage | Adénocarcinome de l'œsophage | Carcinome résécablePays-Bas
-
AstraZenecaComplétéSécurité, Pharmacocinétique, Pharmacodynamique, Effet alimentaireRoyaume-Uni